<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03773042</url>
  </required_header>
  <id_info>
    <org_study_id>HSK3486-201</org_study_id>
    <nct_id>NCT03773042</nct_id>
  </id_info>
  <brief_title>A Study Evaluating Tolerability, Efficacy, and Safety of HSK3486 Injectable Emulsion in Patients</brief_title>
  <official_title>A Phase IIa, Multi-center, Open-label, Non-randomized, Active-controlled, and Dose-escalation Clinical Study Evaluating Tolerability, Efficacy, and Safety of HSK3486 Injectable Emulsion for Sedation/Anesthesia in Patients Undergoing Diagnostic Colonoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sichuan Haisco Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sichuan Haisco Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A double-blind, randomized, active controlled, multi-center, parallel group study comparing
      HSK3486 with Propofol, in patients undergoing a colonoscopy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of successful colonoscopies.</measure>
    <time_frame>From the first dose of the study drug to removal of colonoscope on day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insertion time</measure>
    <time_frame>From the first dose of study drug until insertion of colonoscope on day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The success rate of the colonoscopy procedure</measure>
    <time_frame>From the first dose of the study drug to removal of colonoscope on day 1</time_frame>
    <description>The number of patients who successfully completed the colonoscopy procedure accounted for the proportion of all patients in the dose group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to fully alert</measure>
    <time_frame>From the removal of colonoscopy procedure, until the first of three consecutive MOAA/S scores of 5 on day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to discharge</measure>
    <time_frame>From the removal of colonoscopy procedure, until the first of three consecutive MOAA/S scores of 9 on day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Application of study drug and alternative medication</measure>
    <time_frame>During the colonoscopy procedure on day 1</time_frame>
    <description>Total dosages of study drug and alternative medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mini-Mental State Examinations (MMSE)</measure>
    <time_frame>During the screening and the colonoscopy procedure on day 1</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Colonoscopy</condition>
  <arm_group>
    <arm_group_label>HSK3486</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.1mg/kg, 0.2mg/kg, 0.3mg/kg, 0.4mg/kg, 0.5mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.0mg/kg, 2.0mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HSK3486</intervention_name>
    <description>For induction and maintenance of sedation.</description>
    <arm_group_label>HSK3486</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>For induction and maintenance of sedation.</description>
    <arm_group_label>Propofol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (those who meet all of the following are eligible)

          1. Patients requiring diagnostic colonoscopy with an estimated examination time ≤ 30 min;
             males and females, ASA grade I-II, between 18 and 65 years old (inclusive);

          2. Body mass index (BMI) ≥ 18 and ≤ 30 kg/m2

          3. Respiratory rate between ≥ 10 and ≤ 24 breaths per minute; SpO2 when inhaling &gt; 95%;
             SBP ≥ 90 mmHg; DBP ≥ 60 mmHg; heart rate between ≥ 50 and ≤ 100 beats per minute;

          4. Subjects must understand the procedures and methods of this study, and be willing to
             provide informed consent and to complete the trial in strict accordance with clinical
             trial protocol.

        Exclusion Criteria (those who meet any one of the following are ineligible):

          1. Patients having contraindications to general anesthesia or previous history of
             anesthesia accidents;

          2. Patients with a known sensitivity to propofol, opioids, naloxone, eggs, soy products
             or a medical condition such that these agents were contraindicated;

          3. Patient received any of the following drugs or therapies prior to screening:

               1. Participated in other drug clinical trials within 3 month prior to screening;

               2. In receipt of propofol and/or opioid analgesics within 1 month prior to
                  screening;

          4. The patient has some history or evidence of increased risk of sedation or anesthesia,
             such as cardiovascular disease, respiratory disease, cerebrovascular disease,
             gastrodintestinal disease and other system disease prior to the screening and/or
             baseline period.

          5. Patient whose laboratory parameters measured at screening/prior to enrollment reach
             the following criteria and verified through re-examinations:

               1. ANC ≤ 1.5 x 109/L;

               2. PLT ≤ 80 x 109/L;

               3. Hb ≤ 90 g/L (no blood transfusion within the last 14 days);

               4. AST and ALT ≥ 2.5 x ULN;

               5. TBIL ≥ 1.5 x ULN;

               6. Creatinine ≥ 1.5 x ULN.

          6. History of alcohol abuse within 3 months prior to screening or with a positive result
             of alcohol saliva strip test (before dose);

          7. History of medication abuse within 3 months prior to screening, or a positive urine
             medication test (during screening or before dose administration);

          8. Women who are pregnant or breastfeeding; women of child-bearing potential or men who
             are unwilling to use contraception during the trial; Patients who are planning
             pregnancy within 1 month after the completion of the trial (including male patients);

          9. Potential difficult airway or difficult tracheal intubation, as determined by the
             investigator, and/or history of intubation failure;

         10. Patients determined by the investigator to be unsuitable for participating in this
             trial for any reason.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>December 6, 2018</study_first_submitted>
  <study_first_submitted_qc>December 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2018</study_first_posted>
  <last_update_submitted>December 11, 2018</last_update_submitted>
  <last_update_submitted_qc>December 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

